Trending...
- LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
- WebDrafter Welcomes Honey in the Hollow as a New Marketing Client
- Jacombs Tickets Partners with UEFA to Offer Champions League Tickets
SAN DIEGO, June 17, 2024 ~ In a recent announcement, Primrose Bio, Inc. revealed that it has received a significant equity investment from 1315 Capital, a healthcare-focused growth equity firm based in Philadelphia. This investment will provide the necessary funds for the company to further develop and expand its three major offerings.
Primrose Bio, Inc., also known as "Primrose," is dedicated to developing and licensing manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines. With this new investment, the company is well-positioned to advance its solutions for therapeutic protein and nucleic acid manufacturing with both current and future partners.
One of Primrose's key offerings is Prima RNApols™, which are proprietary RNA polymerase enzymes that have been shown to significantly improve mRNA manufacturing. These enzymes have been found to increase yields by up to 5 times, eliminate double-stranded RNA, and enhance cap incorporation compared to the commonly used T7 RNA polymerase standard.
Another major offering from Primrose is Pfenex Expression Technology®, a validated microbial expression system that has been used in five approved drugs. This technology consistently demonstrates 10-20 times higher yields compared to other systems such as E.coli, CHO, and yeast-based systems. It also boasts an unparalleled success rate in producing complex proteins.
More on The PennZone
Lastly, Primrose offers PeliCRM®, the only commercially available CRM197 conjugate vaccine carrier protein used in approved products. This technology plays a crucial role in the production of vaccines.
Dr. Helge Zieler, CEO of Primrose Bio, Inc., expressed excitement about the partnership with 1315 Capital. "We are thrilled to have the support of such a high-quality organization and team at 1315 Capital who share our vision of expanding opportunities in biomanufacturing technologies for the pharmaceutical industry," he said.
Matt Reber, Partner at 1315 Capital, also shared his enthusiasm for this collaboration. "There has been a tremendous amount of innovation in therapeutics over the last decades, and relatively little in their production systems," he stated. "Primrose's validated technology platforms address an increasingly important challenge facing the industry as drugs get more complex, and pricing pressure continues to mount."
With this new investment, Primrose Bio, Inc. is poised to make significant strides in the biomanufacturing industry and continue to provide cutting-edge solutions for therapeutic protein and nucleic acid manufacturing.
Primrose Bio, Inc., also known as "Primrose," is dedicated to developing and licensing manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines. With this new investment, the company is well-positioned to advance its solutions for therapeutic protein and nucleic acid manufacturing with both current and future partners.
One of Primrose's key offerings is Prima RNApols™, which are proprietary RNA polymerase enzymes that have been shown to significantly improve mRNA manufacturing. These enzymes have been found to increase yields by up to 5 times, eliminate double-stranded RNA, and enhance cap incorporation compared to the commonly used T7 RNA polymerase standard.
Another major offering from Primrose is Pfenex Expression Technology®, a validated microbial expression system that has been used in five approved drugs. This technology consistently demonstrates 10-20 times higher yields compared to other systems such as E.coli, CHO, and yeast-based systems. It also boasts an unparalleled success rate in producing complex proteins.
More on The PennZone
- DayPass llega a ChatGPT y Claude
- DayPass launches in ChatGPT and Claude
- Renkeer Water Quality Sensors Support Efficient Operation of AI Liquid Cooling Systems
- Victor Archibong Expands ItsArchiDuh Creator Brand
- Talented Learning Unveils 2026 LMS Award Winners
Lastly, Primrose offers PeliCRM®, the only commercially available CRM197 conjugate vaccine carrier protein used in approved products. This technology plays a crucial role in the production of vaccines.
Dr. Helge Zieler, CEO of Primrose Bio, Inc., expressed excitement about the partnership with 1315 Capital. "We are thrilled to have the support of such a high-quality organization and team at 1315 Capital who share our vision of expanding opportunities in biomanufacturing technologies for the pharmaceutical industry," he said.
Matt Reber, Partner at 1315 Capital, also shared his enthusiasm for this collaboration. "There has been a tremendous amount of innovation in therapeutics over the last decades, and relatively little in their production systems," he stated. "Primrose's validated technology platforms address an increasingly important challenge facing the industry as drugs get more complex, and pricing pressure continues to mount."
With this new investment, Primrose Bio, Inc. is poised to make significant strides in the biomanufacturing industry and continue to provide cutting-edge solutions for therapeutic protein and nucleic acid manufacturing.
0 Comments
Latest on The PennZone
- Clearnetworx Deploys netElastic vBNG, CGNAT And netVision To Power Fiber Expansion Across Colorado's Western Slope
- Glenn Strange - Iconic Horror actor of Universal Studios Frankenstein's Monster Fame Honored
- Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources
- Hilton Waikiki Beach Resort & Spa Introduces Level 37 Sky Lounge by Casamigos
- Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon
- Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX
- Roots for Boots to Participate in 2026 Adams County Community Foundation Giving Spree
- Timbrana Helps General Contractors Improve Jobsite Visibility and Subcontractor Accountability
- Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1
- Vegan Kingz Expands Direct-Import Wholesale Lineup to Help Commercial Kitchens Cut Ingredient Costs
- Acuvance Survey Finds ERP Integration Remains a Key Challenge as Healthcare Organizations Prepare for AI
- Everything Policy Unveils Their Classroom Resources Behind Every Policy Topic
- Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era
- LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
- Danish company biosuite introduces biotech procurement software to track outsourced R&D commitments
- Ten Ten Ten Announces Alento, Its Initiative to Help Independent Primary Care Thrive
- JFAB Consulting to Celebrate New Brand with Private VIP Event at Acrisure Stadium
- Industrial & systems engineering educator and professional to lead global strategic partnerships for professional society
- Convergence of AI, Wearable Technology, Remote Patient Monitoring and Real-World Healthcare: PomDoctor Ltd. (N A S D A Q: POM)
- Timbrana — Construction Project Awareness Software for General Contractors